Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology
Advertisement
Articles by Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology
Expert oncologist Alex Spira, MD, PhD, FACP, reviews primary results from the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.
Advertisement
Latest Updated Articles
ROS1-Rearranged NSCLC: Updates FromASCOPublished: August 19th 2021 | Updated:
Dr. Spira on the Impact of the PACIFIC-R Trial in Unresectable Stage III NSCLCPublished: September 24th 2021 | Updated:
RET-Fusions in NSCLC: Updates From ASCOPublished: August 12th 2021 | Updated:
NSCLC: FLAURA Trial ResultsPublished: July 8th 2021 | Updated:
ALK-Rearranged NSCLC: Updates From ASCOPublished: August 12th 2021 | Updated:
NSCLC: ADAURA Trial ResultsPublished: July 1st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5